For example, we do not recommend excluding patients under age 60 or over age 85, those with non-amnestic AD phenotypes, or patients with ADAD mutations (aside from patients with mutations that are specifically associated with CAA), and we do not require tau PET or quantitative amyloid PET thresholds for treatment. This evidence concerns the gene MAPT and Alzheimer disease.